Metabolic Uncoupling Following Cardiopulmonary Bypass

Congenit Heart Dis. 2015 Nov-Dec;10(6):E250-7. doi: 10.1111/chd.12285. Epub 2015 Jul 29.

Abstract

Objective: The objective of this study was to characterize the natural history of metabolic uncoupling (type B hyperlactemia and hyperglycemia) following cardiopulmonary bypass (CPB), and to determine the impact of insulin therapy on time to lactate normalization in patients without low cardiac output.

Design: The design used was a retrospective cohort study.

Setting: The study was set in a pediatric cardiac intensive care unit in a tertiary-care urban children's hospital.

Patients: All patients were aged ≤21 years admitted between 2007 and 2013 following cardiac surgery involving CPB with empiric intraoperative corticosteroids.

Eligibility criteria: simultaneous hyperlactemia (≥3.5 mEq/L) and hyperglycemia (≥200 mg/dL) within 48 hours after bypass.

Exclusion criteria: Exclusion criteria were evidence of low cardiac output state, diabetes or postoperative steroid administration.

Interventions: Characteristics were compared between those treated with insulin and those who were not (controls).

Outcome measures: Outcome measures used were time from admission to onset of hyperglycemia and hyperlactemia and time to resolution. Clinical outcomes included duration of mechanical ventilation, length of stay, unplanned readmission/reoperation, hypoglycemia and death.

Results: Of the 1345 patients receiving CPB, 132 (9.8%) met inclusion criteria. Seventy-eight (59%) were treated with insulin, leaving 54 controls. Patient characteristics, surgical complexity and time to onset of hyperglycemia and hyperlactemia were similar between groups. The insulin group had a shorter duration of hyperglycemia. There was no significant difference between groups in time to lactate normalization, ventilator days, length of stay, readmission and reoperation rates. Hypoglycemia (<60 mg/dL) occurred in three patients.

Conclusions: In children with metabolic uncoupling after CPB, insulin use did not shorten the time to lactate normalization or alter clinical outcomes. These findings suggest that type B hyperlactemia with hyperglycemia after CPB will resolve spontaneously and does not warrant specific treatment.

Keywords: Cardiopulmonary Bypass; Congenital Heart Defects; Hyperglycemia; Insulin; Lactate; Pediatric Intensive Care Unit.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Blood Glucose / metabolism*
  • Cardiac Output, Low / blood
  • Cardiac Output, Low / physiopathology
  • Cardiac Output, Low / surgery
  • Cardiopulmonary Bypass / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperglycemia / blood
  • Hyperglycemia / drug therapy
  • Hyperglycemia / etiology*
  • Hyperlactatemia / blood
  • Hyperlactatemia / drug therapy
  • Hyperlactatemia / etiology*
  • Hypoglycemic Agents / therapeutic use
  • Infant
  • Infant, Newborn
  • Insulin / therapeutic use*
  • Lactates / blood*
  • Male
  • Postoperative Complications*
  • Retrospective Studies
  • Risk Factors
  • Stroke Volume / physiology
  • Time Factors
  • Young Adult

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Lactates